Yeah if you believed their minimum quota contracts they would have been making a profit this quarter.
I'm going to have to go through these reports more carefully, but I find reporting that goes to great lengths (word lengths) to point out every single silver lining incredibly difficult to read, so it might take me a couple of days. Sadly, there are very few straight talkers on the ASX. I have a feeling that I will be selling at the end of that read.
Having read the numbers, some questions I will be looking for answers for are:
Why haven't minimum quotas been met? Especially given that
Most large state economies were open for large periods of that quarter?
Were Canadian labs reaching quotas?
What percentage of labs in the wide range of trading conditions were meeting quotas?
Why do the numbers seem to indicate that it was far below 10%?
While I expect good reporting to answer all of the above, another question that I don't expect to be answered is why are they resetting the base for comparison to the month of February, which was already terribly below expectations at the time?
I didn't invest in this company to read a whole lot marketing. There's already an overabundance of rubbish to filter out in our lives.
- Forums
- ASX - By Stock
- OVN
- Ann: Quarterly Business Review & Appendix 4C
Ann: Quarterly Business Review & Appendix 4C, page-10
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OVN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online